Actinium Pharmaceuticals presented the first ever preclinical data from the combination of menin inhibitors with ARC Actimab-A in acute myeloid leukemia models. Menin inhibitors are a class of drug candidates being developed for patients with AML that have a rearrangement of the KMT2A gene.
Sandesh Seth, Actinium's CEO, said, "Across single agent and combination studies, Actimab-A has produced high rates of response, MRD negativity and improved survival in high-risk, relapsed and refractory patients including those with a TP53 mutation and venetoclax failures."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.